RecruitingPhase 3NCT07091630
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Intervention
- Empasiprubart IV(biological)
- Enrollment
- 160 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (19)
- Colorado Springs Neurological Associates, Colorado Springs, Colorado, United States
- Medstar Health Research Institute, Washington D.C., District of Columbia, United States
- Gables Neurology, Miami, Florida, United States
- Paradigm Health System, Slidell, Louisiana, United States
- National Neuromuscular Research Institute, Austin, Texas, United States
- NeuroCarePlus, Houston, Texas, United States
- Peking University First Hospital - Changqiao Campus, Beijing, China
- Nanfang Hospital Southern Medical University, Guangzhou, China
- High Technology Hospital MedCenter Ltd, Batumi, Georgia
- First Medical Clinic LLC, Batumi, Georgia
- Petre Sarajishvili Institute of Neurology, Tbilisi, Georgia
- Aleksandre Aladashvili Clinic, Tbilisi, Georgia
- Curatio JSC, Tbilisi, Georgia
- LTD New Hospitals, Tbilisi, Georgia
- Geo Hospitals, Tbilisi, Georgia
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07091630 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
- RECRUITINGPHASE2NCT06798012A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Takeda
See all trials for Chronic inflammatory demyelinating polyneuropathy →